A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.

We have examined the efficacy, toxicity and host immunological response of two different dose schedules of interleukin 2 (IL-2) given subcutaneously, daily for 3 months in patients with renal cell carcinoma (RCC) or metastatic melanoma (MM). We also examined the effect of adding the immune modulator...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ahmed, F. Y., Leonard, G. A., A'Hern, R., Taylor, A. E., Lorentzos, A., Atkinson, H., Moore, J., Nicolson, M. C., Riches, P. G., Gore, M. E.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 1996
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2077131/
https://ncbi.nlm.nih.gov/pubmed/8855983
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars